Tag
Briefings and ideas about AI healthcare from AI podcast discussions and the research they cite, with links to the original sources.
Google DeepMind's AlphaGenome Atlas precomputes predicted molecular effects of every possible single-letter change in the human genome. A Moonshots panelist cautioned that what combinations of variants mean still needs outcome data.
In an exploratory analysis of 42 lung-fibrosis patients, AI-designed drug rentosertib made protein aging clocks read about three years younger by week four. Mortality clocks didn't significantly shift at 60 mg, and the effect plateaued by week 12.
OpenAI lets health organizations connect authorized patient records to ChatGPT, with summaries citing the chart. On a podcast, Emad Mostaque urged AI double-checks of every health decision within a year or two, a proposal, not practice.
An AI-scripted, AI-voiced episode, labelled as AI, kept 40 to 50% of listeners to the end, says The Diary of a CEO's host, who argues informational podcasting is substitutable while in-person experiences will command a premium.
David Friedberg argued AI can screen a million protein ideas on computers to find ones that might reverse cell aging, without a full theory of the cell. The eye work he cited has reached a first safety trial in people, not restored sight.
GenBio's AIDO Cell simulates a human cell that remembers successive edits and drugs. For now it helps prioritize experiments in two cell lines; lab validation of its novel predictions is underway. A Moonshots panelist called it the end of medicine.
Merck and Moderna said personalized mRNA therapy intismeran autogene plus Keytruda beat Keytruda alone on melanoma recurrence-free and distant-metastasis-free survival in a 1,137-patient phase 3 interim analysis. No effect sizes were released.
Salim Ismail argued Apple's 512GB Mac Studio turns AI spending from a per-token bill into an owned capital asset for law firms and mid-sized healthcare groups. Fellow panelist Dave called it a tiny step by a company he says has no AI strategy.